PX1 Research supplies analytical-grade GHRP-2 (Growth Hormone Releasing Peptide-2) formulated specifically for in vitro assays and preclinical secretagogue pharmacology. Every batch undergoes rigorous RP-HPLC and mass spectrometry testing to guarantee verified purity exceeding 98% for reliable laboratory data.
PX1 Research supplies analytical-grade GHRP-2 (Growth Hormone Releasing Peptide-2) formulated specifically for in vitro assays and preclinical secretagogue pharmacology. Every batch undergoes rigorous RP-HPLC and mass spectrometry testing to guarantee verified purity exceeding 98% for reliable laboratory data.
When purchasing GHRP-2 for laboratory inquiry, researchers require documented chemical purity, precise lot-to-lot consistency, and comprehensive analytical documentation. PX1 Research provides synthetic GHRP-2 lyophilized powder manufactured in domestic GMP-compliant facilities and verified by independent ISO 17025 accredited laboratories. Every order includes a public, lot-specific Certificate of Analysis (COA) detailing identity and purity metrics.
To ensure reproducible experimental conditions in pituitary signaling and somatotrophic axis models, researchers should source compounds verified via high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). Low-grade or improperly characterized peptides introduce confounding variables such as truncated sequences, counter-ion contamination, or trace endotoxins that corrupt cellular assay outcomes.
GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide classified as a ghrelin receptor agonist and growth hormone secretagogue (GHS). It acts primarily on the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein coupled receptor expressed predominantly in the anterior pituitary gland and hypothalamic regions.
In contrast to endogenous ghrelin, GHRP-2 lacks the n-octanoyl post-translational modification, yet retains high binding affinity for GHS-R1a. In vitro binding studies demonstrate that GHRP-2 activates the phospholipase C (PLC) signal transduction pathway, driving intracellular inositol trisphosphate (IP3) generation and triggering transient increases in cytosolic calcium ([Ca2+]i). This calcium influx promotes the exocytosis of stored growth hormone granules from pituitary somatotrophs.
Preclinical studies evaluating growth hormone secretagogues demonstrate that GHRP-2 acts synergistically with endogenous Growth Hormone-Releasing Hormone (GHRH). While GHRH stimulates the cyclic adenosine monophosphate (cAMP) pathway via GHRH receptors, GHRP-2 engages the GHS-R1a receptor to recruit protein kinase C (PKC) signaling. Laboratory models confirm that co-activation of these parallel pathways yields a synergistic, rather than additive, release of GH in somatotroph cultures.
In animal models, administration of GHRP-2 has been utilized to map hypothalamic-pituitary-somatic axis responsiveness under varying physiological conditions. Literature indicates that GHRP-2 also exhibits modest secondary activation of the hypothalamic-pituitary-adrenal (HPA) axis in certain rodent assays, resulting in transient elevations of adrenocorticotropic hormone (ACTH) and cortisol baseline levels. Researchers exploring broader endocrine dynamics often cross-reference these findings against data compiled in the PX1 research library.
Selecting the appropriate compound for GHS-R1a activation depends on the targeted signaling kinetics, secondary receptor cross-reactivity, and desired potency profile. GHRP-2 is frequently evaluated alongside second- and third-generation secretagogues within the same pharmacological class.
When compared to GHRP-6, GHRP-2 demonstrates significantly higher potency in activating GHS-R1a receptors for GH release in pituitary cell culture, while exhibiting a slightly less pronounced impact on hyperphagia signaling pathways in central nervous system models. Conversely, Ipamorelin represents a highly selective pentapeptide secretagogue that stimulates GH release without triggering significant elevations in ACTH, cortisol, or prolactin. Researchers examining non-GHS-R1a mechanisms may also contrast GHRP-2 against GHRH analogs such as CJC-1295. A complete list of available secretagogues and structural analogs can be found in our all peptides catalog.
Achieving complete solubilization and maintaining peptide integrity requires standardized laboratory handling procedures. GHRP-2 is supplied as a lyophilized (freeze-dried) cake or powder sealed under inert gas atmosphere to preserve molecular stability.
For standard in vitro or analytical application, reconstitute GHRP-2 using sterile target-appropriate solvents such as Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride injection solution. Avoid vigorous agitation or vortexing during reconstitution, as high mechanical shear stress can cause peptide denaturation or aggregation. Gently swirl or allow the diluent to flow down the inner wall of the glass vial, permitting the lyophilized matrix to dissolve naturally over 2 to 5 minutes.
Lyophilized GHRP-2 should be stored at -20°C or -80°C in a desiccated environment protected from direct light exposure. Under sub-zero storage conditions, un-reconstituted GHRP-2 maintains structural stability for up to 24 months. Short-term ambient exposure during transit does not degrade the synthetic peptide solid due to the absence of moisture.
Following reconstitution, store liquid solutions at 2°C to 8°C for short-term experimental procedures (not exceeding 30 days when formulated with bacteriostatic preservatives). For extended study timelines, aliquot the reconstituted liquid into single-use polypropylene microtubes and freeze at -80°C to prevent repeated freeze-thaw cycles. Microscopic ice crystal formation during multiple freeze-thaw events breaks peptide backbone bonds and diminishes active compound yield.
Ensuring experimental reproducibility mandates stringent supplier verification standards. PX1 Research adheres to rigorous quality control frameworks to eliminate analytical ambiguities prior to distribution.
Key quality standards verified for every lot of GHRP-2 include:
1. Reversed-Phase HPLC (RP-HPLC): Establishes chromatographic purity, verifying that major peptide peaks exceed 98.0% total area integration without significant degradation fragments or synthesis side-products. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular mass match (theoretical molecular weight: ~817.9 g/mol) to verify sequence correctness. 3. Endotoxin Quantitation (LAL Assay): Measures bacterial endotoxin levels to ensure values remain well below established thresholds (<0.01 EU/μg), protecting sensitive cell cultures from inflammatory artifacts. 4. Residual Solvent & Counter-Ion Analysis: Confirms efficient removal of trifluoroacetic acid (TFA) salts and synthesis solvents.
PX1 Research manufactures and inventories compounds domestically within the United States. Utilizing advanced solid-phase peptide synthesis (SPPS) platforms in ISO/GMP-compliant facilities, we maintain strict control over chemical synthesis, purification, and packaging environments.
Orders dispatch directly from centralized distribution hubs located in California and Arizona, providing rapid transit across North America. Orders placed Monday through Friday prior to cutoff times are fulfilled same-day. Academic institutions and commercial laboratories requiring bulk quantities, custom filling, or contracted lot-reservation can establish direct supply protocols via our wholesale portal.
What is the primary mechanism of GHRP-2 in laboratory research?
GHRP-2 acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a). In preclinical models, it stimulates intracellular calcium mobilization via the phospholipase C pathway, resulting in the exocytosis of growth hormone from anterior pituitary somatotrophs.
How is GHRP-2 verified for chemical purity by PX1 Research?
Every lot of GHRP-2 undergoes analytical testing by an independent ISO 17025 accredited laboratory using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment and Mass Spectrometry (MS) for sequence mass verification.
What solvent is recommended for reconstituting GHRP-2 in laboratory settings?
GHRP-2 is commonly reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride solution depending on the specific in vitro or analytical assay requirements.
What are the recommended storage temperatures for lyophilized GHRP-2?
Lyophilized GHRP-2 powder should be stored long-term at -20°C to -80°C in a desiccated, light-protected environment to prevent hydrolytic degradation.
How does GHRP-2 differ structurally from GHRP-6?
Both are synthetic hexapeptides targeting GHS-R1a; however, GHRP-2 incorporates specific amino acid substitutions (D-Ala-D-2Nal vs D-Lys-D-Trp modifications) that yield higher potency for GH secretion in pituitary cell assays with less pronounced stimulation of central appetite pathways.
What endotoxin controls are applied to PX1 GHRP-2 lots?
PX1 Research subjects GHRP-2 lots to Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain below standard analytical limits (<0.01 EU/μg), avoiding unwanted cellular activation in research models.
Can reconstituted GHRP-2 undergo multiple freeze-thaw cycles?
No. Repeated freeze-thaw cycles induce mechanical stress and thermal disruption that break peptide bonds. Reconstituted solutions should be divided into single-use aliquots before freezing.
Where does PX1 Research ship GHRP-2 from?
All PX1 Research products are manufactured in domestic US facilities and shipped directly from our primary distribution facilities in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.